cardiology database
AHA 2011 Orlando conference coverage
News clinical trials presented at AHA 2011 Orlando
ADOPT, 2011
-
apixaban 2.5mg twice daily, 30 days vs enoxaparin 40mg once daily 6-14 days
DVT prophylaxis - antithrombotics - medical patients
DVT prophylaxis - direct factor Xa inhibitors - all type of patients
DVT prophylaxis - new oral anticoagulants - all type of patients
DVT prophylaxis - new oral anticoagulants - medical patients
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011
-
rivaroxaban 2.5 mg twice daily in addition to standard care vs placebo
acute coronary syndrome - antithrombotics - all type of patient
acute coronary syndrome - anticoagulant - All ACS (including AMI)
acute coronary syndrome - direct factor Xa inhibitors - all type of patients
acute coronary syndrome - antithrombotics - patients with a recent ACS
acute coronary syndrome - new oral anticoagulants - all type of patients
FAST, 2011
-
vs
Choose another conferences:
AHA 2012 Los Angeles
ESC 2012 München
AHA 2011 Orlando
TCT 2011
ESC 2011 Paris
ACC 2011 New Orleans
ESC 2010 Stockholm
ACC 2010 Atlanta
European Society of Cardiology 2009 Congress
ACC.09/i2 Orlando 2009
AHA 2009 Orlando
TCT 2010
AHA 2010 Chicago
ACC 2012
|